CA3013734A1 - Method and composition for treatment and prevention of broad spectrum virus ailments - Google Patents
Method and composition for treatment and prevention of broad spectrum virus ailments Download PDFInfo
- Publication number
- CA3013734A1 CA3013734A1 CA3013734A CA3013734A CA3013734A1 CA 3013734 A1 CA3013734 A1 CA 3013734A1 CA 3013734 A CA3013734 A CA 3013734A CA 3013734 A CA3013734 A CA 3013734A CA 3013734 A1 CA3013734 A1 CA 3013734A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- calcium channel
- treatment
- channel blocker
- verapamil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 241000700605 Viruses Species 0.000 title abstract description 6
- 238000000034 method Methods 0.000 title abstract description 6
- 230000002265 prevention Effects 0.000 title description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 claims abstract description 19
- 239000000480 calcium channel blocker Substances 0.000 claims abstract description 19
- 239000002207 metabolite Substances 0.000 claims abstract description 15
- 239000003085 diluting agent Substances 0.000 claims abstract description 8
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical group C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 18
- 229960001722 verapamil Drugs 0.000 claims description 18
- 208000004898 Herpes Labialis Diseases 0.000 claims description 12
- 206010067152 Oral herpes Diseases 0.000 claims description 10
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 10
- 229960004166 diltiazem Drugs 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 6
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 201000004946 genital herpes Diseases 0.000 claims description 5
- 208000007514 Herpes zoster Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000008174 sterile solution Substances 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 206010072210 Genital herpes zoster Diseases 0.000 claims 6
- 239000000499 gel Substances 0.000 claims 2
- 239000002324 mouth wash Substances 0.000 claims 2
- 229940051866 mouthwash Drugs 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 102000000584 Calmodulin Human genes 0.000 abstract description 7
- 108010041952 Calmodulin Proteins 0.000 abstract description 7
- 230000003612 virological effect Effects 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000000069 prophylactic effect Effects 0.000 abstract description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract description 2
- 241000124008 Mammalia Species 0.000 abstract description 2
- 229910001424 calcium ion Inorganic materials 0.000 abstract description 2
- 238000012423 maintenance Methods 0.000 abstract description 2
- 108020004418 ribosomal RNA Proteins 0.000 abstract description 2
- 230000014616 translation Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 206010028735 Nasal congestion Diseases 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical group C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
- 229960002324 trifluoperazine Drugs 0.000 description 2
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010053459 Secretion discharge Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
In the broadest aspect, the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a mammal for any viral disease that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the post ribosomal RNA to protein translation transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier.
Description
METHOD AND COMPOSITION FOR TREATMENT AND
PREVENTION OF BROAD SPECTRUM VIRUS AILMENTS
FIELD OF THE INVENTION
The invention relates to methods and compositions for the treatment and prevention of broad spectrum of viral ailments comprising a therapeutically effective amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof. a calmodulin blocker and a metabolite thereof. and a pharmaceutical acceptable diluent or carrier.
SUMMARY OF THE INVENTION
The inventor has discovered that pharmaceutical compositions comprising a !Mocker selected from the group consisting of calcium channel blockers. metabolites thereof.
calmodulin blockers and metabolites thereof that have been used to treat medical conditions unrelated to viral infections can effectively suppress intracellular replication of multiple viral species and prevent and treat diseases caused by a wide spectrum of acute or chronic viral infection.
Thus. the invention provides methods and compositions for the treatment and prevention of broad spectrum virus ailments in human beings.
In the broadest aspect the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a mammal for any viral disease that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the post ribosomal RNA to protein translation transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof. and a pharmaceutical acceptable diluent or carrier.
Accordingly, in one aspect. the invention provides a pharmaceutical composition for the treatment and prevention of broad spectrum virus ailments in human beings.
said composition comprising a therapeutically effective amount of a blocker selected from the group consisting of a calcium channel blocker. a metabolite thereof, a calmodulin blocker and a metabolite thereof. and a pharmaceutical acceptable diluent or carrier.
Preferably. the calcium channel blocker is verapamil, diltiazem or felodipine;
and the calmodulin blocker is trifluoperazine.
Preferably. the composition is in the form of a cream, spray. gel, ointment or patch.
Preferably, the composition is in the form of a tablet, a sustained release formulation for systemic use.
Preferably, the composition is in the form of a sterile solution for parenteral injection.
In a still yet further aspect. the invention provides a method of manufacturing a medicament intended for the prevention. and treatment of viral infections characterized in that the medicament is a blocker selected from the group consisting of a calcium channel blocker. a metabolite thereof, a calmodulin blocker and a metabolite thereof;
and admixed with a pharmaceutical acceptable diluent or carrier.
Preferably. the blocker is selected from verapamil, diltiazem, felodipine and trifluoperazine.
Kits comprising pharmaceutical compositions of the invention formulated in sterile unit dosage forms suitable for administration to patients, includes instructions for use in written, oral. videotape. compact disc. other digital electronic form, or other recorded media, are contemplated.
Thus, in a further aspect, the invention provides a kit comprising the above-described compositions and an instruction for using the combination in treating, improving. curing or preventing viral infections.
The appropriate dosage and frequency of treatment may vary depending on the specific symptoms and signs exhibited by the patient. or the clinical situation for prophylactic uses. Other health related factors should also be cortsidered.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
In order that the invention may be better understood. preferred embodiments will now be described by way of example only with reference to the following Examples.
PREVENTION OF BROAD SPECTRUM VIRUS AILMENTS
FIELD OF THE INVENTION
The invention relates to methods and compositions for the treatment and prevention of broad spectrum of viral ailments comprising a therapeutically effective amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof. a calmodulin blocker and a metabolite thereof. and a pharmaceutical acceptable diluent or carrier.
SUMMARY OF THE INVENTION
The inventor has discovered that pharmaceutical compositions comprising a !Mocker selected from the group consisting of calcium channel blockers. metabolites thereof.
calmodulin blockers and metabolites thereof that have been used to treat medical conditions unrelated to viral infections can effectively suppress intracellular replication of multiple viral species and prevent and treat diseases caused by a wide spectrum of acute or chronic viral infection.
Thus. the invention provides methods and compositions for the treatment and prevention of broad spectrum virus ailments in human beings.
In the broadest aspect the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a mammal for any viral disease that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the post ribosomal RNA to protein translation transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof. and a pharmaceutical acceptable diluent or carrier.
Accordingly, in one aspect. the invention provides a pharmaceutical composition for the treatment and prevention of broad spectrum virus ailments in human beings.
said composition comprising a therapeutically effective amount of a blocker selected from the group consisting of a calcium channel blocker. a metabolite thereof, a calmodulin blocker and a metabolite thereof. and a pharmaceutical acceptable diluent or carrier.
Preferably. the calcium channel blocker is verapamil, diltiazem or felodipine;
and the calmodulin blocker is trifluoperazine.
Preferably. the composition is in the form of a cream, spray. gel, ointment or patch.
Preferably, the composition is in the form of a tablet, a sustained release formulation for systemic use.
Preferably, the composition is in the form of a sterile solution for parenteral injection.
In a still yet further aspect. the invention provides a method of manufacturing a medicament intended for the prevention. and treatment of viral infections characterized in that the medicament is a blocker selected from the group consisting of a calcium channel blocker. a metabolite thereof, a calmodulin blocker and a metabolite thereof;
and admixed with a pharmaceutical acceptable diluent or carrier.
Preferably. the blocker is selected from verapamil, diltiazem, felodipine and trifluoperazine.
Kits comprising pharmaceutical compositions of the invention formulated in sterile unit dosage forms suitable for administration to patients, includes instructions for use in written, oral. videotape. compact disc. other digital electronic form, or other recorded media, are contemplated.
Thus, in a further aspect, the invention provides a kit comprising the above-described compositions and an instruction for using the combination in treating, improving. curing or preventing viral infections.
The appropriate dosage and frequency of treatment may vary depending on the specific symptoms and signs exhibited by the patient. or the clinical situation for prophylactic uses. Other health related factors should also be cortsidered.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
In order that the invention may be better understood. preferred embodiments will now be described by way of example only with reference to the following Examples.
2 53 year old male with symptoms of viral upper respiratory infection started experiencing nasal congestion and nasal discharge. Patient sprayed 0.2 ml of Verapamil 2mg/m1 into each nostril and directly into the back of the throat. Within minutes, patient experienced a reduction in nasal congestion and decreased nasal discharge. The nasal continued to slow and stopped after approximately 20 minutes.
After a couple of hours the patient then continued to apply repeated small local applications of 0.1 to 0.2 ml intranasally and orally to throat twice more when the symptoms of nasal congestion started to recurred and again prior to going to sleep that night.
When the patient awoke the next day the upper respiratory symptoms were cleared, but the patient began to experience lower respiratory infectious symptoms of an increasingly productive cough the next day. These lower respiratory symptoms worsened and by the following day the patient was experiencing extreme uncontrolled coughing episodes. The patient went on Vcrapamil 80 mg q6-8 hours. Prior to starting Verapamil, the patient had profuse clear mucus discharge from the lungs and was experiencing prolonged and frequent coughing spells. After taking his first dose of Verapamil. within 10-20 minutes the patient noticed a profound reduction in coughing and a significant reduction in volume of sputum being cleared from the lungs. Within 30-60 minutes of the first dose, the cough was infrequent and mostly non-productive. For the next four days. whenever the patient went beyond 6-8 hours of last 80 mg dose. he began to experience increasing productive coughing repeatedly demonstrating a relationship between declining serum Verapamil levels and increasing severity- of his bronchitis/pulmonary symptoms and each time that the patient took the 80 mg Verapamil tablet there was a dramatic reduction in pulmonary discharge and reduction in coughing for over 6 hours before symptoms.
Patient A with recurrent cold sores was given Diltizem 100mg/m1 and asked to apply topically at the first signs of a cold sore. The patient observed that in the initial tingling phase prior to the eruption if he applied the cream, the infection could be prevented and if application was delayed until eruption was visible. he could minimize the severity, reduce the size and complete healing clearance would occur in 2-4 days in.stead of lasting the usual 7 days.
After a couple of hours the patient then continued to apply repeated small local applications of 0.1 to 0.2 ml intranasally and orally to throat twice more when the symptoms of nasal congestion started to recurred and again prior to going to sleep that night.
When the patient awoke the next day the upper respiratory symptoms were cleared, but the patient began to experience lower respiratory infectious symptoms of an increasingly productive cough the next day. These lower respiratory symptoms worsened and by the following day the patient was experiencing extreme uncontrolled coughing episodes. The patient went on Vcrapamil 80 mg q6-8 hours. Prior to starting Verapamil, the patient had profuse clear mucus discharge from the lungs and was experiencing prolonged and frequent coughing spells. After taking his first dose of Verapamil. within 10-20 minutes the patient noticed a profound reduction in coughing and a significant reduction in volume of sputum being cleared from the lungs. Within 30-60 minutes of the first dose, the cough was infrequent and mostly non-productive. For the next four days. whenever the patient went beyond 6-8 hours of last 80 mg dose. he began to experience increasing productive coughing repeatedly demonstrating a relationship between declining serum Verapamil levels and increasing severity- of his bronchitis/pulmonary symptoms and each time that the patient took the 80 mg Verapamil tablet there was a dramatic reduction in pulmonary discharge and reduction in coughing for over 6 hours before symptoms.
Patient A with recurrent cold sores was given Diltizem 100mg/m1 and asked to apply topically at the first signs of a cold sore. The patient observed that in the initial tingling phase prior to the eruption if he applied the cream, the infection could be prevented and if application was delayed until eruption was visible. he could minimize the severity, reduce the size and complete healing clearance would occur in 2-4 days in.stead of lasting the usual 7 days.
3 Patient B with recurrent cold sores was given Verapamil 200rng/m1 and asked to apply at the first signs of a cold sore. The patient observed that in the initial tingling phase if he applied the cream. the infection could be prevented and if application was delayed until eruption was visible. he could minimize the severity. reduce the size and complete healing 001m:ice could occur in 2-4 days instead of lasting the u.sual 7 days.
Male patient with a long history of recunent Genital Herpes was using Di'linen When questioned by the inventor about the frequency of recurrences of his genital herpes before and after starting Di!Einem. the patient reported that before he was having several episode pur year, and that after starting Diltiazem there had been only about 1-2 yisodes per year. that they were much smaller and seemed to heat much quicker vvhen on when Diltiazem.
HIV patient took Verapamil 240 mg SR daily for 2 weeks before repeat blood work and showed significant rise in T4 helper counts.
gNAMPLE 6 39 year old woman with a three day history of fever. chills. muscle aches and nausea.
On the second and third days the patieM developed increasing diarrhea. On the morning of the third day the patient was experiencing loose. watery stools with a cramps and lower abdominal pain. Patient had 6 watery bowel movements and was going to the washroom frequently before starting Verapamil 120 mg tablets, taking one every 8 hours.
Within one hour of taking the first Verapamil the abdominal cramping began subsiding and her stools began to become more formed and diarrhea improved.
Male patient with a long history of recunent Genital Herpes was using Di'linen When questioned by the inventor about the frequency of recurrences of his genital herpes before and after starting Di!Einem. the patient reported that before he was having several episode pur year, and that after starting Diltiazem there had been only about 1-2 yisodes per year. that they were much smaller and seemed to heat much quicker vvhen on when Diltiazem.
HIV patient took Verapamil 240 mg SR daily for 2 weeks before repeat blood work and showed significant rise in T4 helper counts.
gNAMPLE 6 39 year old woman with a three day history of fever. chills. muscle aches and nausea.
On the second and third days the patieM developed increasing diarrhea. On the morning of the third day the patient was experiencing loose. watery stools with a cramps and lower abdominal pain. Patient had 6 watery bowel movements and was going to the washroom frequently before starting Verapamil 120 mg tablets, taking one every 8 hours.
Within one hour of taking the first Verapamil the abdominal cramping began subsiding and her stools began to become more formed and diarrhea improved.
4 Elderly patient with Herpes Zoster infection on the upper left abdomen.
Patient took Verapamil 120 mg SR twice daily and noted reduced pain, reduced rash and rapid healing of lesions.
Patient took Verapamil 120 mg SR twice daily and noted reduced pain, reduced rash and rapid healing of lesions.
5
Claims (15)
1. A pharmaceutical composition for use in the treatment of cold sores, genital herpes, or Herpes Zoster, comprising a calcium channel blocker, or a metabolite thereof, and a pharmaceutically acceptable diluent or carrier, wherein said calcium channel blocker is verapamil or diltiazem.
2. A pharmaceutical composition for use in the treatment of cold sores or Herpes Zoster, as claimed in Claim 1 wherein said calcium channel blocker is verapamil.
3. A pharmaceutical composition for use in the treatment of core sores or genital herpes, as claimed in Claim 1 wherein said calcium channel blocker is diltiazem.
4. A pharmaceutical composition as claimed in any one of Claims 1 to 3 wherein said composition is in the form of a cream, spray, mouth wash, gel, ointment or patch for intra-nasal or topical administration.
5. A pharmaceutical composition as claimed in any one of Claims 1 to 3 wherein said composition is in the form of a tablet, or a sustained release formulation, for systemic use.
6. A pharmaceutical composition as claimed in any one of Claims 1 to 3 wherein said composition is in the form of a sterile solution for parenteral injection.
7. A use of a composition for the treatment of cold sores, genital herpes, or Herpes Zoster, comprising a calcium channel blocker, or a metabolite thereof, and a pharmaceutically acceptable diluent or carrier, wherein said calcium channel blocker is verapamil or diltiazem.
8. A use of a composition for the treatment of cold sores or Herpes Zoster, as claimed in Claim 7, wherein said calcium channel blocker is verapamil.
9. A use of a composition for the treatment of cold sores or genital herpes, as claimed in Claim 7 wherein said calcium channel blocker is diltiazem.
10. A use as claimed in any one of Claims 7 to 9 wherein said composition is in the form of a cream, spray, mouth wash, gel, ointment or patch, for intra-nasal or topical administration.
11. A use as claimed in any one of Claims 7 to 9 wherein said composition is in the form of a tablet, or a sustained release formulation, for systemic use.
12. A use as claimed in any one of Claims 7 to 9 wherein said composition is in the form of a sterile solution for parenteral injection.
13. A method of manufacturing a medicament intended for treatment of cold sores, genital herpes, or Herpes Zoster, characterized in that said medicament comprises a calcium channel blocker, or a metabolite thereof, wherein said blocker is admixed with a pharmaceutically acceptable diluent or carrier, and wherein said calcium channel blocker is verapamil or diltiazem.
14. A method of manufacturing a medicament intended for the treatment of cold sores or Herpes Zoster, as claimed in Claim 13, wherein said calcium channel blocker is verapamil.
15. A method of manufacturing a medicament intended for the treatment of cold sores or genital herpes, as claimed in Claim 13 wherein said calcium channel blocker is diltiazem.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3013734A CA3013734C (en) | 2009-12-03 | 2009-12-03 | Method and composition for treatment and prevention of broad spectrum virus ailments |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2687013A CA2687013C (en) | 2009-12-03 | 2009-12-03 | Method and composition for treatment and prevention of broad spectrum virus ailments |
| CA3013734A CA3013734C (en) | 2009-12-03 | 2009-12-03 | Method and composition for treatment and prevention of broad spectrum virus ailments |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2687013A Division CA2687013C (en) | 2009-12-03 | 2009-12-03 | Method and composition for treatment and prevention of broad spectrum virus ailments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3013734A1 true CA3013734A1 (en) | 2011-06-03 |
| CA3013734C CA3013734C (en) | 2020-01-14 |
Family
ID=44114205
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2687013A Active CA2687013C (en) | 2009-12-03 | 2009-12-03 | Method and composition for treatment and prevention of broad spectrum virus ailments |
| CA3013734A Active CA3013734C (en) | 2009-12-03 | 2009-12-03 | Method and composition for treatment and prevention of broad spectrum virus ailments |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2687013A Active CA2687013C (en) | 2009-12-03 | 2009-12-03 | Method and composition for treatment and prevention of broad spectrum virus ailments |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US10350190B2 (en) |
| EP (2) | EP3216453B1 (en) |
| CA (2) | CA2687013C (en) |
| WO (1) | WO2011066657A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3081325B1 (en) * | 2018-05-23 | 2020-10-09 | Univ Claude Bernard Lyon | DILTIAZEM FOR USE IN THE TREATMENT OF MICROBIAL INFECTIONS |
| FR3106055B1 (en) | 2020-01-13 | 2022-01-28 | Centre Nat Rech Scient | COMBINATION OF DILTIAZEM AND OTHER ANTIVIRAL AGENTS |
| FR3108033B1 (en) | 2020-03-10 | 2023-04-21 | Univ Claude Bernard Lyon | ANTIVIRAL COMPOUNDS AND THEIR COMBINATIONS FOR TREATING SARS-CoV-2 VIRAL INFECTION |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4800081A (en) * | 1984-04-18 | 1989-01-24 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections |
| US4663317A (en) | 1984-04-18 | 1987-05-05 | Board Of Regents, University Of Texas System | Methods and compositions for treating viral infections |
| KR890004691B1 (en) * | 1985-07-02 | 1989-11-25 | 키 파마슈티칼스, 인코포레이티드 | Composition for the treatment of chronic obstructive pulmonary disease |
| US4849412A (en) | 1986-06-05 | 1989-07-18 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections |
| JPH04368338A (en) | 1991-06-12 | 1992-12-21 | Taisho Pharmaceut Co Ltd | Antitussive agent |
| US7479498B2 (en) | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| US20050245502A1 (en) * | 1999-08-23 | 2005-11-03 | Phoenix Biosciences | Treatments for viral infections |
| US7470718B2 (en) * | 2000-10-03 | 2008-12-30 | Albert Einstein College Of Medicine Of Yeshiva University | Method for treating a demyelinating condition |
| ATE358486T1 (en) | 2000-11-09 | 2007-04-15 | Contrimmune Biotechnology Inc | USE OF XESTOSPONGIN C TO TREAT OR PREVENT HIV INFECTION |
| WO2003062388A2 (en) * | 2002-01-16 | 2003-07-31 | The Regents Of The University Of California | Inhibition of rna function |
| AUPS022802A0 (en) * | 2002-01-31 | 2002-02-21 | Macfarlane Burnet Institute For Medical Research And Public Health Limited, The | Anti-viral compounds |
| WO2005089639A2 (en) * | 2004-03-16 | 2005-09-29 | Talarico M D Matthew T | Method for vascular dysregulation |
| KR101646249B1 (en) * | 2008-08-11 | 2016-08-16 | 엘지전자 주식회사 | Method and apparatus of transmitting information in wireless communication system |
| WO2010026602A2 (en) | 2008-09-05 | 2010-03-11 | International Centre For Genetic Engineering And Biotechnology | Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis |
-
2009
- 2009-12-03 CA CA2687013A patent/CA2687013C/en active Active
- 2009-12-03 CA CA3013734A patent/CA3013734C/en active Active
-
2010
- 2010-12-03 US US13/513,639 patent/US10350190B2/en active Active
- 2010-12-03 EP EP17168653.8A patent/EP3216453B1/en active Active
- 2010-12-03 WO PCT/CA2010/001926 patent/WO2011066657A1/en active Application Filing
- 2010-12-03 EP EP10834131.4A patent/EP2506854B1/en active Active
-
2019
- 2019-05-28 US US16/423,225 patent/US10888541B2/en active Active
-
2021
- 2021-01-11 US US17/146,010 patent/US20210128514A1/en not_active Abandoned
-
2023
- 2023-02-27 US US18/114,305 patent/US20230233506A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2506854A4 (en) | 2013-05-22 |
| EP3216453A1 (en) | 2017-09-13 |
| CA2687013C (en) | 2018-09-04 |
| CA2687013A1 (en) | 2011-06-03 |
| US20230233506A1 (en) | 2023-07-27 |
| WO2011066657A1 (en) | 2011-06-09 |
| US20190274992A1 (en) | 2019-09-12 |
| EP2506854B1 (en) | 2017-05-03 |
| US10888541B2 (en) | 2021-01-12 |
| EP3216453B1 (en) | 2019-05-15 |
| US20210128514A1 (en) | 2021-05-06 |
| EP2506854A1 (en) | 2012-10-10 |
| CA3013734C (en) | 2020-01-14 |
| US10350190B2 (en) | 2019-07-16 |
| US20120245145A1 (en) | 2012-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230233506A1 (en) | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker | |
| RU2221561C2 (en) | Vitamin e and its esters for topical treatment of mucosa pathology | |
| Schutz et al. | Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat | |
| JP2008255089A (en) | Epithelium improving agent | |
| US5331012A (en) | Topical pharmaceutical preparation for fever blisters and other viral infections and method of use | |
| WO2010151004A2 (en) | Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids | |
| CA2323213C (en) | Treatment of respiratory disease and otitis media | |
| JP2006515361A (en) | Method for treating or preventing symptoms of herpes virus infection | |
| SHAFFER et al. | Use of Benadryl for Urticaria and Related Dermatoses: A Preliminary Report | |
| CA2130770A1 (en) | Treatment of upper respiratory tract infections | |
| WO2016121147A1 (en) | Enema for rectal application | |
| JP5930332B2 (en) | Use of sprayable compositions comprising ambroxol | |
| WO2011070125A1 (en) | Mucoadhesive buccal tablets for the treatment of orofacial herpes | |
| PT2106258E (en) | Ibuprofen against coughing | |
| RU2173155C1 (en) | Wound-healing, anti-inflammatory and anti-infectious medicinal preparation | |
| JPH08268884A (en) | Use of 7-substituted-2-aminotetralin for preparing medicinalcomposition being useful for therapy of septic shock and antipyretic and antiphlogistic medicinal composition | |
| WO2005069731A2 (en) | Method for treating oral aphthous stomatitis and oral mucositis | |
| JP2001089375A (en) | Composition for common cold | |
| CA2413923A1 (en) | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor | |
| CN1751684A (en) | Novel form of Asimidazole for treating nasal polyls or its disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180809 |